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Background
Heart failure (HF) is characterised by alterations in fatty
acid and glucose metabolism. We aimed to determine if
myocardial lipid is increased in HF with reduced
(HFrEF) and preserved (HFpEF) ejection fraction (EF),
and assess whether it is related to cardiac structure and
function.
Methods
25 HFrEF due to dilated cardiomyopathy (DCM), 18
HFpEF (defined by EF >50%, abnormal diastolic function,
maximum oxygen consumption <80% predicted for age,
height and gender, with a cardiac limitation in exercise)
and 28 normal volunteers were prospectively recruited. All
subjects underwent cardiovascular magnetic (MR) reso-
nance at 3T for the determination of left ventricular (LV)
volumes and function, and cardiac 1H MR spectroscopy to
quantify myocardial lipid/water (%).
Results
As expected DCM patients had significantly increased
LV volumes and reduced EF, whilst HFpEF patients had
significantly increased LV mass to end-diastolic volume
ratio (LV mass/EDV). Importantly, cardiac lipid was
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Table 1 Clinical characteristics of patients with reduced (HFrEF), preserved (HFpEF) ejection fraction and normal
controls.
HFrEF (n = 25) HFpEF (n = 18) Normals (n = 28) P value
Age (years) 60 ± 11* 74 ± 6** 61 ± 5 <0.001
Female, n (%) 8 (32) 12 (67) 12 (43) 0.075
NYHA class, n (%)
I 3 (12) 0 0 -
II 21 (84) 18 (100) 0 -
III 1 (4) 0 0 -
Body mass index (kg/m2) 28 ± 5 28 ± 6 27± 4 0.29
E’ - 4.5 ± 1.2 13.1 ± 3.5 0.001
E/E’ ratio - 10.7 ± 2.7 7.6 ± 3.0 0.002
E/A ratio - 0.7 ± 0.26 1.0 ± 0.3 0.001
Blood glucose 5.4 ± 1.0 5.5 ± 1.1 5.2 ± 1.0 0.55
Free fatty acids 0.44 ± 0.22 0.49 ± 0.29 0.54 ± 0.30 0.46
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increased in both HFrEF and HFpEF when compared to
normal controls (cardiac lipid/water 0.67±0.42% in
HFrEF; 1.06±0.83% in HFpEF versus normal controls
0.44±0.17, all p<0.05), with HFpEF group having the
highest level of cardiac lipid (Table 1, Figure 1). In
DCM patients, cardiac lipid negatively correlated with
LVEF (r=-0.33, p=0.03) and positively correlated with
LV size (r=0.54, p<0.001). In HFpEF, cardiac lipid posi-
tively correlated with age (r=0.41, p=0.008) and LV
mass/EDV (r=0.37, p=0.02). Although HFpEF patients
were significantly older, with age positively correlated
with cardiac lipid, multiple regression analysis showed
that age is not an independent predictor of cardiac lipid.
Conclusions
This is the first study to demonstrate that myocardial
steatosis occurs in both HFrEF and HFpEF and is related
to parameters of LV remodeling. This suggests that myo-
cardial lipid may play a role in the pathophysiological
processes of LV remodeling in both HFrEF and HFpEF.
Cardiac lipid accumulation may be a potential therapeutic
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Table 1 Clinical characteristics of patients with reduced (HFrEF), preserved (HFpEF) ejection fraction and normal con-
trols. (Continued)
Triglycerides (mmol/L) 1.5 ± 0.7 1.2 ± 0.4 1.1 ± 0.3 0.12
Low-density lipoprotein (mmol/L) 2.9 ± 0.9 2.4 ± 0.7 3.1 ± 1.1 0.07
High-density lipoprotein (mmol/L) 1.4 ± 0.5 1.6 ± 0.4 1.4 ± 0.4 0.49
CMR findings
Cardiac lipid/water (%) 0.67 ± 0.42† 1.06 ± 0.83** 0.44 ± 0.17 0.001
LV end-diastolic volume (ml) 233 ± 82† 111 ± 21‡ 144 ± 28 <0.001
LV ejection fraction (%) 38 ± 9† 74 ± 6‡ 69 ± 5 <0.001
LV mass index (g/m2) 80 ± 25† 54 ± 12‡ 55 ± 11 <0.001
LV mass/EDV (g/mL) 0.69 ± 0.18* 0.91 ± 0.22** 0.74 ± 0.16 0.003
* p<0.05 vs HFpEF and p>0.05 vs normal; ** p<0.05 vs normal.
† p<0.05 vs HFpEF and normal; c‡ p>0.05 vs normal.
Figure 1 Cardiac lipid content in HFrEF, HFpEF and normal
subjects. *p<0.05 vs HFpEF and normal; **p<0.05 vs normal.
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